America Movil S.A.B. De C.V. (NYSE:AMX) said fourth-quarter net income plunged 77.8 percent to 3.612 billion Mexican pesos from 16.286 billion pesos in the previous year, hit by increased depreciation and amortization charges and higher comprehensive financing costs.On Wednesday shares of America Movil S.A.B. de C.V. (NYSE:AMX) closed at $20.52. Company’s sales growth for last 5 years was 17.90% and EPS growth for next 5 years is recorded as 4.80%.
Heat Biologics, Inc. (NASDAQ:HTBX), announced the presentation of data demonstrating the incorporation of T-cell costimulatory fusion proteins into Heat’s gp96-Ig vaccine platform, at a Keystone Symposia on “Tumor Immunology — Multidisciplinary Science Driving Combination Therapy,” which was held in Banff, Canada. The study is part of ongoing development work at Heat to introduce a novel combination immunotherapy product simultaneously expressing its gp96-Ig vaccine and individual T-cell costimulatory fusion proteins. Heat Biologics, Inc. (NASDAQ:HTBX) in last trading activity advanced 5.80% to close at $5.47. Company weekly performance is 8.32% while its quarterly performance stands at 9.84%. Heat Biologics, Inc. (NASDAQ:HTBX) is -35.65% away from its 52 week high.
Anika Therapeutics, Inc. (NASDAQ:ANIK) announced that it has filed regulatory submissions in both the United States and Europe seeking the approval of Cingal, the Company’s novel HA plus steroid single-injection treatment for osteoarthritis of the knee. Anika submitted its application for CE Mark approval to commercialize Cingal in the European Union and also filed its premarket approval application (PMA) with the U.S. Food and Drug Administration to allow for marketing and distribution in the United States. On last trading day Anika Therapeutics Inc. (NASDAQ:ANIK) increased 1.63% to close at $40.61. Its volatility for the week is 3.34% while volatility for the month is 3.90%. ANIK’s sales growth for past 5 years was 16.00% and its EPS growth for past 5 years was 35.00%. Anika Therapeutics Inc. (NASDAQ:ANIK) monthly performance is 2.50%.
FireEye (NASDAQ: FEYE) reported Q4 EPS of ($0.38), $0.11 better than the analyst estimate of ($0.49). Revenue for the quarter came in at $143 million versus the consensus estimate of $141.49 million. FireEye sees Q1 2015 EPS of ($0.53)-($0.49), versus the consensus of ($0.53). FireEye sees FY2015 EPS of ($1.90)-($1.80), versus the consensus of ($1.87).FireEye, Inc. (NASDAQ:FEYE) has 0.90% insider ownership while its institutional ownership stands at 63.60%. In last trading activity company’s stock closed at $36.55.
On February 5, 2015, the Compensation Committee of the Board of Directors of Informatica Corporation (NASDAQ:INFA) approved the allocations, methodologies, and metrics for the payment of bonuses for 2015, if any, to Informatica’s executive officers. On last trading day Informatica Corporation (NASDAQ:INFA) advanced 0.77% to close at $43.39. Its volatility for the week is 1.51% while volatility for the month is 2.67%. INFA’s sales growth for past 5 years was 15.90% and its EPS growth for past 5 years was 9.30%. Informatica Corporation (NASDAQ:INFA) monthly performance is 21.64%.